Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases with an initial focus on cancer.


Updates from The Motley Fool

Latest updates on Merrimack Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Merrimack Pharmaceuticals.
3 Stocks Begging for a Buyout

Here's why it could make sense for Twitter, GoPro, and Merrimack Pharmaceuticals to get acquired.



Stock Performance

View Interactive MACK Charts
Sponsored by

Key Data Points

Primary metrics and data points about Merrimack Pharmaceuticals.
Current Price: $3.04
Prev Close: $3.01
Open: $3.01
Bid: $3.01
Ask: $3.05
Day's Range: $2.98 - $3.05
52wk Range: $2.83 - $9.02
Volume: 1,963,820
Avg Vol 2,010,402
Market Cap: $397M
P/E (ttm): -2.49
EPS (ttm): ($1.21)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Merrimack Pharmaceuticals.
CAPS Rating 3 out of 5
 
91 Outperform
9 Underperform
CAPS All Stars
 
14 Outperform
3 Underperform

How do you think Merrimack Pharmaceuticals will perform against the market?



You pick for Merrimack Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Robert J. Mulroy, CEO

70% Approve

Based on 16 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases with an initial focus on cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers